A Randomized, Double-blinded, Multicenter Study in Healthy Adults to Evaluate Safety and Immunogenicity of AV7909 Administered At Two Dose Levels on Two Vaccination Schedules, Including a Primary Series and Booster Doses
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Anthrax vaccine adsorbed adjuvanted Emergent BioSolutions (Primary)
- Indications Anthrax
- Focus Adverse reactions; Pharmacodynamics
- Acronyms ABESt
Most Recent Events
- 30 Aug 2024 Planned End Date changed from 1 Jul 2026 to 1 Aug 2026.
- 30 Aug 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Aug 2025.
- 30 Aug 2024 Status changed from recruiting to active, no longer recruiting.